Format

Send to

Choose Destination
Nanomedicine (Lond). 2014 May;9(6):839-49. doi: 10.2217/nnm.14.1. Epub 2014 Jan 17.

Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma.

Author information

1
Department of Industrial Chemistry, "TosoMontanari", University of Bologna, Via Risorgimento 4, 40136, Bologna, Italy.

Abstract

AIM:

Targeted biocompatible nanoplatforms presenting multiple therapeutic functions have great potential for the treatment of cancer.

MATERIALS & METHODS:

Multifunctional nanocomposites formed by polymeric nanoparticles (PNPs) containing two cytotoxic agents - the drug alisertib and silver nanoparticles - were synthesized. These PNPs have been conjugated with a chlorotoxin, an active targeting 36-amino acid-long peptide that specifically binds to MMP-2, a receptor overexpressed by brain cancer cells.

RESULTS:

The individual and synergistic activity of these two cytotoxic agents against glioblastoma multiforme was tested both in vitro and in vivo. The induced cytotoxicity in a human glioblastoma-astrocytoma epithelial-like cell line (U87MG) was studied in vitro through a trypan blue exclusion test after 48 and 72 h of exposure. Subsequently, the PNPs' biodistribution in healthy animals and their effect on tumor reduction in tumor-bearing mice were studied using PNPs radiolabeled with (99m)Tc.

CONCLUSION:

Tumor reduction was achieved in vivo when using silver/alisertib@PNPs-chlorotoxin.

KEYWORDS:

alisertib; cancer; glioblastoma; nanoprecipitation; organic coating; polymeric nanoparticle; radiolabeling; silver nanoparticle; toxicity; tumor reduction

PMID:
24433240
DOI:
10.2217/nnm.14.1
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center